Azora Therapeutics, Inc.

Azora Therapeutics, Inc.

AZR - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$55.04M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Azora Therapeutics, Inc.Azora Therapeutics, Inc.-0.2--690073%--
$8.80

Current Fair Value

128.5% upside

Undervalued by 128.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$55.04 Million
Enterprise Value$55.02 Million
Earnings per Share$-11.93
Beta1.64
Outstanding Shares14,296,323

Return

Return on Equity-690073.00%ROE
Return on Assets-535198.66%
Return on Invested Capital-363111.61%

Valuation & Multiples

P/E Ratio-0.21P/E Ratio
PEG-0.01PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-0.87
Enterprise Value to Net Income-1
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 18, 2026
EPS Estimate
-$0.30
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 11, 2027
EPS Estimate
-$0.25
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Adial Pharmaceuticals Inc

2,018 employees
CEO: Cary J. Claiborne

Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.

Questions & Answers